TY - JOUR
T1 - An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
AU - Weichselbaum, Ralph R.
AU - Ishwaran, Hemant
AU - Yoon, Taewon
AU - Nuyten, Dimitry S. A.
AU - Baker, Samuel W.
AU - Khodarev, Nikolai
AU - Su, Andy W.
AU - Shaikh, Arif Y.
AU - Roach, Paul
AU - Kreike, Bas
AU - Roizman, Bernard
AU - Bergh, Jonas
AU - Pawitan, Yudi
AU - van de Vijver, Marc J.
AU - Minn, Andy J.
PY - 2008
Y1 - 2008
N2 - Individualization of cancer management requires prognostic markers and therapy-predictive markers. Prognostic markers assess risk of disease progression independent of therapy, whereas therapy-predictive markers identify patients whose disease is sensitive or resistant to treatment. We show that an experimentally derived IFN-related DNA damage resistance signature (IRDS) is associated with resistance to chemotherapy and/or radiation across different cancer cell lines. The IRDS genes STAT1, ISG15, and IFIT1 all mediate experimental resistance. Clinical analyses reveal that IRDS(+) and IRDS(-) states exist among common human cancers. In breast cancer, a seven-gene-pair classifier predicts for efficacy of adjuvant chemotherapy and for local-regional control after radiation. By providing information on treatment sensitivity or resistance, the IRDS improves outcome prediction when combined with standard markers, risk groups, or other genomic classifiers
AB - Individualization of cancer management requires prognostic markers and therapy-predictive markers. Prognostic markers assess risk of disease progression independent of therapy, whereas therapy-predictive markers identify patients whose disease is sensitive or resistant to treatment. We show that an experimentally derived IFN-related DNA damage resistance signature (IRDS) is associated with resistance to chemotherapy and/or radiation across different cancer cell lines. The IRDS genes STAT1, ISG15, and IFIT1 all mediate experimental resistance. Clinical analyses reveal that IRDS(+) and IRDS(-) states exist among common human cancers. In breast cancer, a seven-gene-pair classifier predicts for efficacy of adjuvant chemotherapy and for local-regional control after radiation. By providing information on treatment sensitivity or resistance, the IRDS improves outcome prediction when combined with standard markers, risk groups, or other genomic classifiers
U2 - https://doi.org/10.1073/pnas.0809242105
DO - https://doi.org/10.1073/pnas.0809242105
M3 - Article
C2 - 19001271
SN - 0027-8424
VL - 105
SP - 18490
EP - 18495
JO - PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
JF - PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
IS - 47
ER -